📊 LNAI Key Takeaways
Is LNAI a Good Investment? Thesis Analysis
Lunai Bioworks exhibits critical financial distress with negative stockholders' equity (-$13.5M), near-zero and collapsing revenue ($24.3K, -203.8% YoY), and negative operating cash flow (-$2.4M). The company cannot sustain operations or service $20.2M liabilities with current economics, presenting severe bankruptcy risk.
Why Buy LNAI? Key Strengths
- Minimal capital expenditure requirements reduce ongoing cash burn beyond operating losses
- Pharmaceutical sector positioning retains potential value if pipeline assets attract partnership or acquisition
- Small asset base could facilitate orderly restructuring or strategic transaction
LNAI Investment Risks to Consider
- Negative stockholders' equity of -$13.5M indicates technical insolvency
- Revenue collapse of 203.8% YoY with near-zero topline suggests complete operational failure
- Operating cash outflow of -$2.4M unsustainable; current cash of $491.6K provides only ~3 months runway
- Critically low liquidity (0.03x current ratio) with $20.2M total liabilities; inability to meet short-term obligations
- Negative interest coverage (-6.8x) indicates inability to service debt from operations; no Form 4 insider activity suggests management loss of confidence
Key Metrics to Watch
- Monthly cash burn rate and remaining runway before insolvency
- Any revenue stabilization or partnership/licensing deal announcements
- Stockholders' equity trajectory and capital raise activity
- Changes in total liabilities indicating restructuring or debt repayment
LNAI Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
LNAI Profitability Ratios
LNAI vs Healthcare Sector
How Lunai Bioworks Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LNAI Overvalued or Undervalued?
Based on fundamental analysis, Lunai Bioworks Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LNAI Balance Sheet & Liquidity
LNAI 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Lunai Bioworks Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.91 indicates the company is currently unprofitable.
LNAI Growth Metrics (YoY)
LNAI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2018 | N/A | $15.0K | N/A |
| Q3 2017 | $42.5K | -$207.6K | N/A |
| Q2 2017 | $42.5K | -$275.5K | N/A |
| Q3 2016 | $42.5K | -$207.6K | N/A |
| Q2 2016 | $42.5K | -$275.5K | N/A |
| Q3 2014 | $925 | -$371.5K | N/A |
| Q2 2014 | $31.6K | -$343.9K | N/A |
| Q1 2014 | $31.6K | -$399.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LNAI Capital Allocation
LNAI SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Lunai Bioworks Inc. (CIK: 0001527728)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LNAI
What is the AI rating for LNAI?
Lunai Bioworks Inc. (LNAI) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LNAI's key strengths?
Claude: Minimal capital expenditure requirements reduce ongoing cash burn beyond operating losses. Pharmaceutical sector positioning retains potential value if pipeline assets attract partnership or acquisition.
What are the risks of investing in LNAI?
Claude: Negative stockholders' equity of -$13.5M indicates technical insolvency. Revenue collapse of 203.8% YoY with near-zero topline suggests complete operational failure.
What is LNAI's revenue and growth?
Lunai Bioworks Inc. reported revenue of $24.3K.
Does LNAI pay dividends?
Lunai Bioworks Inc. does not currently pay dividends.
Where can I find LNAI SEC filings?
Official SEC filings for Lunai Bioworks Inc. (CIK: 0001527728) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LNAI's EPS?
Lunai Bioworks Inc. has a diluted EPS of $0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LNAI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lunai Bioworks Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LNAI stock overvalued or undervalued?
Valuation metrics for LNAI: ROE of N/A (sector avg: 15%), net margin of 4,193.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LNAI stock in 2026?
Our dual AI analysis gives Lunai Bioworks Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LNAI's free cash flow?
Lunai Bioworks Inc.'s operating cash flow is $-2.4M, with capital expenditures of $1.2K. FCF margin is -9,959.9%.
How does LNAI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4,193.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).